Skip to main content

Table 3 Active screening strategies considered in the probability of cost-effectiveness calculations

From: Cost-effectiveness modelling to optimise active screening strategy for gambiense human African trypanosomiasis in endemic areas of the Democratic Republic of Congo

No. Strategy Screening coverage, c (%) Screening interval, t (years) Active zero- detections, za Total cost (<DOLLAR/>) Total DALYs ACER (<DOLLAR/>/DALY) ICER (<DOLLAR/>/DALY)
1 Passive surveillance only1 0 N/A N/A 25754 [12267, 40807] 2488.8 [1207.8, 3912.6] Minimum cost Minimum cost
2 Biennial screening with one zero for cessation 55 2 1 42517 [23546, 62968] 1338.9 [437.8,1755.7] 14.6 14.62
3 Biennial screening with two zeros for cessation 55 2 2 43066 [24432, 63133] 1339.4 [436.3,1755.5] 15.1 Dominated
4 Biennial screening with three zeros for cessation 55 2 3 43501 [25092, 63266] 1340.1 [434.8,1756.5] 15.4 Dominated
5 Annual screening with one zero for cessation 55 1 1 48885 [26628, 72263] 1027.9 [570.3, 2262.7] 15.8 20.43
6 Annual screening with two zeros for cessation 55 1 2 49571 [27896, 72428] 1027.7 [570.6, 2264.3] 16.3 2501.44
7 Annual screening with three zeros for cessation 55 1 3 50163 [28670, 72806] 1027.4 [572.9, 2261.9] 16.7 2772.35
  1. 1The comparator strategy. 2Relative to Strategy 1. 3Relative to Strategy 2. 4Relative to Strategy 5. 5Relative to Strategy 6.
  2. We show the mean total cost (to nearest dollar) and the total number of DALYs (to the nearest 0.1 DALYs) for each strategy with the 95% prediction intervals across all stochastic realisations. The ACER is the change in cost over the change in DALYs averted as compared to the baseline strategy, whilst the ICER is compared to the next best strategy (given in the table footnotes). Costs are denominated in 2018 US dollars
\